Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.

doi:10.1002/ajh.27138

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.

American journal of hematology - 1 Feb 2024

Gangat Naseema, Karrar Omer, Iftikhar Moazah, McCullough Kristen, Johnson Isla M, Abdelmagid Maymona, Abdallah Mostafa, Al-Kali Aref, Alkhateeb Hassan B, Begna Kebede H, Mangaonkar Abhishek, Saliba Antoine N, Hefazi Torghabeh Mehrdad, Litzow Mark R, Hogan William, Shah Mithun, Patnaik Mrinal M, Pardanani Animesh, Badar Talha, Murthy Hemant, Foran James, Palmer Jeanne, Sproat Lisa, Khera Nandita, Arana Yi Cecilia, Tefferi Ayalew

Abstract excerpt

Venetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND-AML was to identify molecular predictors of treatment response to Ven-HMA and survival; European LeukemiaNet (ELN) genetic risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Disease-Free Survival

Share to Genotype

Share to Leukemia, Myeloid, Acute

Share to Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 38071734
DOI: 10.1002/ajh.27138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.PMID 38071734Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese PatientsSemantic proximity Read ↗

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Semantic proximity Read ↗

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemiaSemantic proximity Read ↗

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Semantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.